Market capitalization | $49.95m |
Enterprise Value | $55.35m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.53 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-19.90m |
Free Cash Flow (TTM) Free Cash Flow | $-8.50m |
Cash position | $1.63m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.13 -0.13 |
8%
8%
|
|
EBITDA | -20 -20 |
23%
23%
|
EBIT (Operating Income) EBIT | -20 -20 |
23%
23%
|
Net Profit | -75 -75 |
22%
22%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Head office | United States |
CEO | David Weinstein |
Employees | 25 |
Founded | 2011 |
Website | renovarobio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.